Assessing and managing pulmonary impairment in those who have completed TB treatment in programmatic settings

Int J Tuberc Lung Dis. 2019 Sep 1;23(9):1044-1045. doi: 10.5588/ijtld.19.0168.

Authors

A D Harries¹, J M Chakaya²

Affiliations

¹ International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
² International Union Against Tuberculosis and Lung Disease, Paris, France, Department of Medicine, Therapeutics, Dermatology and Psychiatry, Kenyatta University, Nairobi, Kenya.

PMID: 31615616
DOI: 10.5588/ijtld.19.0168

No abstract available

Publication types

Letter
Comment

MeSH terms

Antitubercular Agents
Benin
Humans
Lung
Patients
Prevalence
Tuberculosis, Pulmonary*

Substances

Antitubercular Agents